

# COVID-19 adaptive humoral immunity models: non-neutralizing versus antibody-disease enhancement scenarios

Antoine Danchin<sup>\*†</sup>; Oriane Pagani-Azizi<sup>‡</sup>; Gabriel Turinici<sup>§</sup>; Ghazlane Yahiaoui<sup>¶</sup>

Oct 2020

## Abstract

The interplay between the virus, infected cells and the immune responses to SARS-CoV-2 is still under debate. Extending the basic model of viral dynamics we propose here a formal approach to describe the neutralizing versus non-neutralizing scenarios and compare with the possible effects of antibody-dependent enhancement (ADE). The theoretical model is consistent with data available from the literature and conclusions show that, while both non-neutralizing scenarios and ADE give rise to similar final virus clearance, the non-neutralizing antibodies can induce permanent high levels of antibody production with documented unfavorable impact on the disease progression and outcome. We also discuss the implications on secondary infections.

## 1 Background

SARS-CoV-2 is a new virus from the coronavirus family, responsible for the ongoing COVID-19 pandemic. To date, there are more than 35 million cases and over a million deaths worldwide [1]. SARS-CoV-2 is the third betacoronavirus to severely infect humans appearing in the last 20 years, after SARS-CoV-1 and MERS-CoV. This motivates a growing need for efficient drugs and/or vaccines, not only for the time being but also in anticipation of a future coronavirus resurgence.

---

\*The order of the authors is alphabetic

†Institut Cochin, Paris, France.

*E-mail address:* [Antoine.Danchin@normalesup.org](mailto:Antoine.Danchin@normalesup.org)

‡CEREMADE - ESPCI Paris PSL, Paris, France.

*E-mail address:* [Oriane.Pagani-Azizi@espci.fr](mailto:Oriane.Pagani-Azizi@espci.fr)

§Université Paris Dauphine - PSL Research University, Paris, France.

*E-mail address:* [Gabriel.Turinici@dauphine.fr](mailto:Gabriel.Turinici@dauphine.fr)

¶Mathematical Institute, University of Oxford, Oxford, United Kingdom.

*E-mail address:* [Ghazlane.Yahiaoui@maths.ox.ac.uk](mailto:Ghazlane.Yahiaoui@maths.ox.ac.uk)

However, initial promising successes of antiviral treatments raised also the possibility of negative side-effects. On the vaccine front, an auto-immune disease (leading to temporary suspension of clinical trials) appeared during the AstraZeneca vaccine trial (Sept 9th 2020); altogether this context demonstrated the importance of understanding qualitatively and quantitatively the immune response to primary infection and also to challenges (vaccines belong to both categories). In particular, relevant mathematical models of the immune dynamics can be of interest to understand and predict the complicated behavior often observed.

We focus here on adaptive humoral immunity (the antibody-mediated immunity) and refer to future works for an extension to the cellular and/or innate immune system. In particular, our goal is to investigate the nature of the response to secondary (challenge) infection using a viral dynamics model.

### 1.1 Available evidence detailing the antibody response

For clinical reasons and also for the understanding of those studying vaccines, antibody responses are of paramount importance; SARS-CoV-2 specific antibodies are usually detected during the second week after illness onset (see [2, 3]) and remain active thereafter for an unknown time span (see however [4] for recent information). Antibody responses are mainly directed against the RBD-spike and nucleocapsid proteins. However, the neutralization capacities of these specific antibodies is still under discussion, especially since non-neutralizing antibodies can enhance infection through a process called antibody-dependent enhancement (hereafter abbreviated 'ADE') [5, 6, 7, 8]. This has been recently emphasized in the set up of clinical trials (see for example [9]), in a general discussion of the prospects of vaccination [10] and in a perspective accounting for the present situation in terms of SARS-CoV-2 vaccines, therapies and immunity [11, 12]

The present academic interpretation of the ADE is that it occurs through virus-antibody immunocomplexes that facilitate virus internalization in host cells that do not express virus receptor but Fc receptors. ADE is induced when the antibody-virus stoichiometry is below the threshold for neutralization, [5, 6]. As a consequence, neutralizing antibodies may enhance infection when their concentrations fall below a key occupancy threshold, and some poorly neutralizing antibodies may strongly increase infection over a wide dose-response range. ADE has been demonstrated in vitro for many viral infections, including that triggered by SARS-CoV-1 which was reported to infect in vitro human macrophages (see [7]) and human B cell lines via an ADE pathway, (see [8]). Moreover, Qidi Wang et al. reported that a specific spike protein epitope elicited antibodies which could enhance infection via ADE, while other epitopes induced neutralizing antibodies in non-human primates. Furthermore, the authors showed that a SARS-CoV-1 inactivated vaccine could induce ADE and lung pathology in experimental rhesus monkeys [13]. In contrast, Martial Jaume and co-authors showed that vaccine candidates which mediated in vitro ADE infection could still be neutralizing and protective in vivo on rhesus macaques,

[8]. Moreover, in most cases, ADE infected cells do not support viral replication, [7, 8]. Instead, ADE may trigger cell apoptosis and promote tissue inflammation and injury with the release of pro-inflammatory cytokines from infected cells, [6, 14]. As a result, whether ADE actually happens in SARS-CoV-1 infected humans and is a factor of disease severity is still a debated research subject since no in vivo human evidence has been demonstrated yet (but this statement is very time-dependent given the present intense research on SARS-CoV-2). Note however, that SARS-CoV-1 infected patients who developed a higher and earlier antibody response were associated with worse clinical outcome. An early antibody response may be weakly neutralizing compared to a later one. As a consequence, a high concentration of those antibodies could lead to ADE and enhancement of infection.

The question of ADE and the link between antibody dynamics and disease evolution is still unclear for COVID-19. J. Zhao et al. reported a strong positive correlation between disease severity and high antibody titers two weeks after illness onset. The antibody level is considered as a risk factor for severe evolution, independently from age, gender and comorbidities [15]. In another study, Wenting Tan et al also came to the same conclusion: higher titers of anti-N IgM and anti-N IgG are observed for severe patients [16]. Finally, Baoqing Sun et al observed that severe patients had higher levels N-IgG than S-IgG after the symptoms onset. However, according to the authors, whether N-specific antibodies can block virus infection is still open to question [17]. The secretion of a high level of non-neutralizing antibody supports the hypothesis of ADE for COVID-19 which can partially explain some clinical complications. In contrast, Mehul S. Suthar et al concluded that the appearance of high titer neutralizing antibody responses early after the infection was promising and may offer some degree of protection against re-infection [18]. This result seems to be confirmed in a recent study in which SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates. However, rhesus macaques do not develop severe clinical complications as reported in human patients, suggesting that if rhesus macaques produce neutralizing antibodies, transposition of this observation to humans is still to be investigated [19]. Finally, a recent study on a recovered cohort of COVID-19 patients showed that elderly patients had significantly higher levels of antibodies than younger patients. However, severe and critical patients were excluded from the study because they received passive antibody treatment before sample collection. As a result, the authors could not directly evaluate the effect of antibodies on virus clearance or disease progression in COVID-19 patients [20]. This suggests that if elderly patients tend to develop higher titers of antibodies, those may not be systematically associated with worse clinical evolution. What should rather be answered is whether disease severity is systematically associated with high antibody levels.

On the other hand, the vaccine community is increasingly aware of this need (see discussion on ADE in [11, 10, 12]) and studies along these lines are required.

Another motivation comes from the fact that the adaptive immune system response starts in about a week; on the other hand in many mild forms infection is resolved in around a week while on the contrary severe forms may at first start

as mild and only then become severe; a simplistic view may indicate that the innate immune response is very efficient while the adaptive immune system response may be detrimental. In this case, everyone with a mild first infection (i.e., mostly dealt with by the innate immune system) will, upon re-infection, see a adaptive immune rising faster (once the memory is in place, its response is faster than the innate immune response) and thus the detrimental effects could be visible for people previously having experienced mild forms, e.g., low age class individuals.

## 1.2 Evidence on re-infection

The possible unfavorable outcomes of a secondary infection (challenge) following a primary SARS-CoV-2 infection were described in various situations (see for example [10.1093/cid/ciaa1436]), but an increasing body of evidence highlights the Kawasaki-like syndrome as a possible negative outcome, see [21, 22, 23, 24, 25].

An Italian study [23] indicates that the immune response to SARS-CoV-2 is responsible for the appearance of a pediatric Kawasaki-like syndrome (Kawasaki-like disease or Multisystem Inflammatory Syndrome in Children MIS-C in the US). In this study, 8 to 10 children have been tested positive to IgG, IgM or both (the infection to SARS-CoV-2 preceded the development of the syndrome) and 2 only in PCR (the infection was simultaneous). SARS-CoV-2 infected children who developed the Kawasaki-like syndrome (KLS) were on average older and more severely hit than other children victims of the classical Kawasaki syndrome.

The same phenomena has been observed in the US and UK [21, 24, 25]. Academic studies begin to investigate the interplay between COVID-19 and the MIS-C [26].

The causes of the development of the Kawasaki disease are still unknown. The best accepted hypothesis is that of an abnormal immune response that occurs as a result of the infection provoked by one of several pathogenic agents for the genetically susceptible patients. The triggering pathogens have not yet been identified.

To account for the peaks of the KLS cases following an infection with SARS-CoV-2, two hypothesis may be formulated: the antibodies produced by the children can induce the initiation of an autoimmune disease and syndromes similar to the Kawasaki syndrome. The second hypothesis is an ADE-type mechanism.

## 1.3 Background summary

To summarize, the question of antibody protection and immune system reaction to a virus is still largely under debate. To progress in this discussion, we investigated here the role of ADE in the pathogenesis of COVID-19 in a primary and secondary infection. We propose a mathematical model of the immune response

and virus dynamics that includes the possibility of non-neutralizing antibodies and / or ADE.

## 2 Methods

### 2.1 Mathematical model

We present below the viral and immune response model. The viral-host interaction (excluding the immune response) is called the basic model of virus dynamics. It has been extensively validated both theoretically and experimentally, see [27, eq (3.1) page 18], [28, eqns. (2.3)-(2.4) page 26] and references therein. See also [29, 30, 31] for general overviews of mathematical immunology.

The model involves several classes: that of the target cells, denoted  $T$ , the infected cells, denoted  $I$ , the free virus denoted  $V$  and the antibodies denoted  $A$ . The model is illustrated in figure 1.




Figure 1: Graphical illustration of the flow in the model (1)-(5).

Target cells  $T$ , which in our case are the epithelial cells with ACE2 receptors located, for instance in the respiratory tracts including lungs, nasal and trachea/bronchial tissues, are produced at a rate  $\Lambda$  and die at rate  $\mu$ . The parameters  $\Lambda$  and  $\mu$  define tissue dynamics in the absence of infection, see also section A.1. When these susceptible cells meet free virus particles  $V$ , they become infected at a rate  $\beta_0$ . Furthermore, target cells can also become infected via ADE if virus entry is mediated by antibodies. The parameter  $\beta_1$  represents the rate of ADE infection route which is the result of a three-species interaction:  $T$ ,  $A$  and  $V$ .

Infected (initially target) cells, denoted  $I$ , die at a rate  $\delta$ . Note that this death rate will often be larger than the death rate of uninfected cells because viruses cause cell damage and cell death, [28, 27]. Infected cells produce new virus particles at a rate  $\omega$ , and the free virus particles which have been released from infected cells decay at a rate  $c$  called the clearance rate.

Free virions are neutralized by antibodies  $A$ , which can block virus entry into cells but also facilitate phagocytosis, at a rate  $b$ . Finally, the antibodies can be stimulated by the free virus with a production rate  $a$  while it declines at a rate of  $\sigma$  (see for instance [28, eq. (9.4) p.126]). The complete model reads (all constants are positive):

$$dT/dt = \Lambda - \mu T - \beta(A)VT \quad (1)$$

$$dI/dt = \beta(A)VT - \delta I \quad (2)$$

$$dV/dt = \omega I - cV - bAV \quad (3)$$

$$dA/dt = aVA - \sigma A \quad (4)$$

$$\beta(A) = \beta_0 + \beta_1 A. \quad (5)$$

Several hypotheses in this model need to be further documented. The first one is that all infected cells including ADE infected cells support viral replication and can produce virus. However, to date, it is still unclear whether ADE infected cells can support viral replication in vivo, [7], [8]. Here we choose not to distinguish between virus productive and non productive infected cells to keep the model simple. For the same reason, we do not discriminate between neutralizing and non neutralizing antibodies but consider both as members of the same class, the antibodies neutralizing capacity will therefore be the average of the neutralizing and non-neutralizing species and the average is described by the parameter  $b$ ; on the other hand the ADE magnitude will be monitored by parameter  $\beta_1$ . These parameters are the most important part of the immune response and the object of our study.

## 3 Results

### 3.1 Theoretical results

We refer the reader to the Appendix C for the rigorous statements concerning the theoretical properties of the model (1)-(5). We analyzed the equilibria of the model but the main conclusion is that stochastic events prevent the stable equilibrium state to be reached in practice, cf. section A.5. The parameters  $b$  and  $\beta_1$  are shown to be the most important for the viral-host-antibody dynamics.

### 3.2 Empirical results

Taking into account the available data from the literature and the methodology in section B we used as baseline the following parameters:

We focus on the following scenario :

$\mu$	$\Lambda$	$\omega$	$\beta_0$	$\beta_1$	$\delta$	$c$	$b$	$a$	$\sigma$
0.033	$3.3 \times 10^4$	$2 \times 10^3$	$2 \times 10^{-8}$	0	$10^{-1}$	3	10	$6 \times 10^{-7}$	$6 \times 10^{-3}$

Table 1: Baseline parameters use in numerical simulations of the model (1)-(4)

- **Step 1:** the patient undergoes a first infection of SARS-CoV-2 without ADE ( $\beta_1 = 0$ ).
- **Step 2:** The infection is controlled and the patients is cured few weeks after infection.
- **Step 3:** A few months later, there is a challenge from a slightly different new coronavirus which triggers ADE ( $\beta_1 > 0$ ).

The numerical simulation for the first infection corresponding to parameters in table 1 is shown in figure 2.

There is a 10% fall of target cells which either become infected or naturally die. The viral load peaks around day 5 after symptoms onset at  $10^6$  copies/ml. While SARS-CoV-1 viral load, as MERS-CoV, peaked around 10 days after symptoms onset, most studies agree that SARS-CoV-2 viral load peaks sooner, around day 5, [32],[33]. Concerning antibodies, they increase sharply until week 2 then slower until a month after infection and start to decrease within 2-3 months [34], [35]. Qualitative agreement is observed with clinically observed variations variations of viral load and antibodies concentration depicted in figure 3 (see references in the figure).

The equilibrium state (19) when  $\beta_1 = 0$  (no ADE present) is reached after 4 years for all variables in figure 2. However, viral load and infected cells reach a minimum close to 0 within 6 month post-infection before increasing and oscillating toward equilibrium state (19) (simulations not shown here). Therefore, if the virus load is null close to the minimum, all other variables decrease towards 0 and the infection has vanished. The equilibrium state (19) is stable but not reached in practice as the patient is cured. When there is no ADE, decreasing the neutralizing capacities of antibodies leads on the one hand to a higher viral load peak but on the other hand to higher antibodies concentrations. The less neutralizing the more abundant antibodies are to compensate so that the infection is always solved (see figure 7).

Next we investigated in figure 4 the possibility of the ADE mechanism present ( $\beta_1 > 0$ ), for a range of possible parameter  $\beta_1$  values. We plot all variables upon challenge with the same neutralizing capacity for antibodies. ADE can be triggered by several mechanisms, such as non-neutralizing antibodies or sub-optimal concentration of neutralizing antibodies, which, for simplicity, are not distinguished in this model. A higher ADE parameter leads to more destroyed target cells, more infected cells, more viral load and more antibodies. However the antibodies concentration is restricted by an upper limit. There is a threshold when increasing  $\beta_1$  does not increase significantly the antibody population (see figure 9). Therefore a higher  $\beta_1$  ADE parameter cannot be




Figure 2: Numerical simulation of the first infection without ADE for model (1)-(4) and parameters in table 1.




Figure 3: 3a : Clinically observed typical variation of SARS-CoV-2 viral load in nasopharyngeal swab normalised using cell quantification. Data taken from [32, figure 3 page 703]. 3b : Typical time variations for IgG. Data taken from [36, figure 2 page 1085].

compensated by more antibodies as a lower neutralizing capacity was already present for the first infection. For example, unlike  $\beta_1 = 10^{-10}$  and  $\beta_1 = 0$ , if  $\beta_1 = 10^{-9}$  the viral load directly stabilises to its equilibrium state (21), without reaching a minimum close to 0 while oscillating (simulation not shown here). In this case, the infection wins (leading to respiratory function disruption and possibly patient death).

Next we performed the contrary analysis: we used, for the secondary infection, two possible values ( $b = 3.16$  and  $b = 10$ ) of the parameter  $b$  (i.e., antibodies neutralizing capacity) while fixing  $\beta_1$ . In this case the viral load does not significantly differ between the values  $b = 3.16$  and  $b = 10$ , but antibodies and destroyed target cells change more dramatically and are significantly higher during the first weeks of the disease, (see figure 5). For  $b = 3.16$ , the viral load still oscillates but do not reach small values, its minimum being  $3 \times 10^2$  copies/ml, before increasing and stabilizing towards the equilibrium state described in formulas (21).

## 4 Discussion

We investigated the immune response to SARS-CoV-2 infection and re-infection through a numerical model; the model that can also take into account the possible presence of ADE, either on first infection or to a challenge (secondary or re-infection with a different phenotype, vaccine, etc.).

As to date there is no clear evidence that ADE occurs in COVID-19 severe




Figure 4: The effect of the ADE parameter  $\beta_1$  (the model (1)-(4)). The secondary infection has fixed neutralizing antibodies capacity  $b$  but we investigate several  $\beta_1$  (ADE) parameter values; for all other parameters we use the nominal values given in table 1.




Figure 5: The effect of the neutralizing  $b$  parameter. The secondary infection has lower neutralizing antibodies capacity  $b = 3.16$ . We fixed ADE parameter  $\beta_1$  and considered all other parameters of the model (1)-(4) at their nominal values in table 1.

patients, we assume that ADE only happens upon challenge.

We started from a classic viral-host dynamics ([28],[37]) that we modified by adding parameter  $\beta_1$  to account for a possible ADE mechanism. In order to keep the model at its lowest complexity, we do not distinguish between ADE triggering antibodies and neutralizing antibodies.

We conducted a theoretical study of our system by computing equilibrium states and stability with and without ADE. We showed that stochastic events prevent the stable equilibrium state to be reached in practice and identified parameters  $b$  and  $\beta_1$  to be crucial in the precise dynamics of our system.

Then, we calibrated our parameters values in coherence with references from the literature and available clinical data published in recent studies, [32], [35], on viral load and antibodies concentration. We tested our model with our scenario. We saw that without ADE, the antibody lower neutralizing capacity was systematically compensated with higher concentrations of antibody leading to viral clearance. On the other side, adding ADE was not always associated with viral clearance. Simulations and equilibrium analysis showed that antibody concentration had an upper limit which prevented higher ADE to be compensated by an unlimited antibody quantity. Therefore, ADE should be taken in consideration as a serious risk in vaccine development or disease understanding and treatment.

On the other hand, we showed that the results are sensitive to the neutralizing antibody capacity (the  $b$  parameter); note that a decrease of this parameter can occur in several situations, for instance due to immune function decay, due to the malfunctioning of the antibody immunodominance mechanism that ends up selecting too many weakly neutralizing antibodies or due to miscalibrated therapeutic interventions. Independent of the cause, such a decrease of the neutralizing capacity is susceptible to imply a substantial deterioration of the outcome.

As any other, our model contains of course several limitations. First, we considered all infected cells to support viral replication, including ADE-infected cells. Concerning SARS-CoV-2, the questions of ADE is still under debate, but for SARS-CoV-1 in vitro ADE evidence suggested abortive viral replication in ADE infected cells. Therefore, if we changed the model (1)-(4) to include this distinction, equilibrium state would change and ADE may be compensated. Similarly, we did not distinguish between former antibodies and novel antibodies secreted upon challenge. This would imply more parameters and change equilibrium levels but without inherently changing variables behaviour. Regarding parameters, we did not have enough exploitable available data to train our model and fit parameters better. Finally, an unique model can hardly capture the extreme variability of COVID-19 clinical outcomes, see [38]; some studies proposed that some of the variability come from genetics, see e.g., [39] where genetic information from roughly 4,000 people from Italy and Spain was correlated to severity of COVID-19. This may lead to a variability of our model parameters in the form of random variables.

The more science will shed light on the full picture of SARS-CoV-2, the more our model can input complex and precise details. In the meantime, the main

take-home message is that, with parameters consistent with the available clinical data, the neutralizing capacity and ADE mechanisms may play an important immunological role into the primary and secondary infection outcomes.

## Acknowledgements

Ghozlane Yahiaoui is supported by the Engineering and Physical Sciences Research Council (EPSRC): CDT Grant Ref. EP/L015811/1.

## References

- [1] John's Hopkins University. *COVID-19 Map - Johns Hopkins Coronavirus Resource Center*. <https://coronavirus.jhu.edu/map.html>. (Visited on 06/30/2020).
- [2] Quan-Xin Long et al. "Antibody responses to SARS-CoV-2 in patients with COVID-19". en. In: *Nature Medicine* 26.6 (June 2020). Number: 6 Publisher: Nature Publishing Group, pp. 845–848. ISSN: 1546-170X. DOI: 10.1038/s41591-020-0897-1. URL: <https://www.nature.com/articles/s41591-020-0897-1> (visited on 07/15/2020).
- [3] Kelvin Kai-Wang To et al. "Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study". en. In: *The Lancet Infectious Diseases* 20.5 (May 2020), pp. 565–574. ISSN: 1473-3099. DOI: 10.1016/S1473-3099(20)30196-1. URL: <http://www.sciencedirect.com/science/article/pii/S1473309920301961> (visited on 06/16/2020).
- [4] Jeffrey Seow et al. "Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection". en. In: *medRxiv* (July 2020). Publisher: Cold Spring Harbor Laboratory Press, p. 2020.07.09.20148429. ISSN: 2014-8429. DOI: 10.1101/2020.07.09.20148429. URL: <https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1> (visited on 09/28/2020).
- [5] Adam Taylor et al. "Fc receptors in antibody-dependent enhancement of viral infections". eng. In: *Immunological Reviews* 268.1 (Nov. 2015), pp. 340–364. ISSN: 1600-065X. DOI: 10.1111/imr.12367.
- [6] Akiko Iwasaki and Yexin Yang. "The potential danger of suboptimal antibody responses in COVID-19". eng. In: *Nature Reviews. Immunology* 20.6 (2020), pp. 339–341. ISSN: 1474-1741. DOI: 10.1038/s41577-020-0321-6.
- [7] Ming Shum Yip et al. "Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus". eng. In: *Virology Journal* 11 (May 2014), p. 82. ISSN: 1743-422X. DOI: 10.1186/1743-422X-11-82.

- [8] Martial Jaume et al. “Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc $\gamma$ R pathway”. eng. In: *Journal of Virology* 85.20 (Oct. 2011), pp. 10582–10597. ISSN: 1098-5514. DOI: 10.1128/JVI.00671-11.
- [9] Moderna. *Clinical study protocol*. <https://www.modernatx.com/sites/default/files/mRNA-1273-P30> Accessed: 2010-10-19. Aug. 2020.
- [10] Laura DeFrancesco. “Whither COVID-19 vaccines?” In: *Nature Biotechnology* 38.10 (Oct. 2020), pp. 1132–1145. ISSN: 1546-1696. DOI: 10.1038/s41587-020-0697-7. URL: <https://doi.org/10.1038/s41587-020-0697-7>.
- [11] Wen Shi Lee, Adam K. Wheatley, Stephen J. Kent, and Brandon J. DeKosky. “Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies”. In: *Nature Microbiology* 5.10 (Oct. 2020), pp. 1185–1191. ISSN: 2058-5276. DOI: 10.1038/s41564-020-00789-5. URL: <https://doi.org/10.1038/s41564-020-00789-5>.
- [12] Gregory A. Poland, Inna G. Ovsyannikova, and Richard B. Kennedy. “SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates”. English. In: *The Lancet* 0.0 (Oct. 2020). Publisher: Elsevier. ISSN: 0140-6736, 1474-547X. DOI: 10.1016/S0140-6736(20)32137-1. URL: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32137-1/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32137-1/abstract) (visited on 10/14/2020).
- [13] Qidi Wang et al. “Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates”. eng. In: *ACS infectious diseases* 2.5 (2016), pp. 361–376. ISSN: 2373-8227. DOI: 10.1021/acsinfecdis.6b00006.
- [14] Sheng-Fan Wang et al. “Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins”. eng. In: *Biochemical and Biophysical Research Communications* 451.2 (Aug. 2014), pp. 208–214. ISSN: 1090-2104. DOI: 10.1016/j.bbrc.2014.07.090.
- [15] Juanjuan Zhao et al. “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”. en. In: *Clinical Infectious Diseases* (2020). DOI: 10.1093/cid/ciaa344. URL: <https://academic-oup-com.proxy.insermbiblio.inist.fr/cid/advance-article/doi/10.1093/cid/ciaa344/5812996> (visited on 06/16/2020).
- [16] Wenting Tan et al. “Viral Kinetics and Antibody Responses in Patients with COVID-19”. en. In: *medRxiv* (Mar. 2020). Publisher: Cold Spring Harbor Laboratory Press, p. 2020.03.24.20042382. DOI: 10.1101/2020.03.24.20042382. URL: <https://www.medrxiv.org/content/10.1101/2020.03.24.20042382v1> (visited on 06/30/2020).

- [17] Baoqing Sun et al. “Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients”. In: *Emerging Microbes & Infections* 9.1 (Jan. 2020). Publisher: Taylor & Francis. eprint: <https://doi.org/10.1080/22221751.2020.1762515>, pp. 940–948. ISSN: null. DOI: 10.1080/22221751.2020.1762515. URL: <https://doi.org/10.1080/22221751.2020.1762515> (visited on 06/16/2020).
- [18] Mehul S Suthar et al. “Rapid generation of neutralizing antibody responses in COVID-19 patients”. In: *medRxiv* (May 2020). DOI: 10.1101/2020.05.03.20084442. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274246/> (visited on 07/15/2020).
- [19] Abishek Chandrashekar et al. “SARS-CoV-2 infection protects against rechallenge in rhesus macaques”. en. In: *Science* (May 2020). Publisher: American Association for the Advancement of Science Section: Research Article. ISSN: 0036-8075, 1095-9203. DOI: 10.1126/science.abc4776. URL: <https://science.sciencemag.org/content/early/2020/05/19/science.abc4776> (visited on 07/15/2020).
- [20] Fan Wu et al. “Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications”. en. In: *medRxiv* (Apr. 2020). Publisher: Cold Spring Harbor Laboratory Press, p. 2020.03.30.20047365. DOI: 10.1101/2020.03.30.20047365. URL: <https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2> (visited on 07/15/2020).
- [21] Centers for Disease Control and Prevention (CDC). *HAN Archive - 00432 — Health Alert Network (HAN)*. en-us. <https://emergency.cdc.gov/han/2020/han00432.asp>. May 2020. URL: <https://emergency.cdc.gov/han/2020/han00432.asp> (visited on 06/12/2020).
- [22] Katherine Harmon Courage. *What we know about the new Covid-19-linked illness in children*. en. Library Catalog: [www.vox.com](http://www.vox.com), <https://www.vox.com/2020/5/13/21257568/kids-covid-19-kawasaki-pediatric-multisymptom-inflammatory-disease>. May 2020. URL: <https://www.vox.com/2020/5/13/21257568/kids-covid-19-kawasaki-pediatric-multisymptom-inflammatory-disease> (visited on 06/12/2020).
- [23] Lucio Verdoni et al. “An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study”. English. In: *The Lancet* 395.10239 (June 2020). Publisher: Elsevier, pp. 1771–1778. ISSN: 0140-6736, 1474-547X. DOI: 10.1016/S0140-6736(20)31103-X. URL: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31103-X/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31103-X/abstract) (visited on 07/02/2020).
- [24] Shelley Riphagen, Xabier Gomez, Carmen Gonzalez-Martinez, Nick Wilkinson, and Paraskevi Theocharis. “Hyperinflammatory shock in children during COVID-19 pandemic”. English. In: *The Lancet* 395.10237 (May 2020). Publisher: Elsevier, pp. 1607–1608. ISSN: 0140-6736, 1474-547X. DOI: 10.1016/S0140-6736(20)31094-1. URL: <https://www.thelancet.com>.

- [com/journals/lancet/article/PIIS0140-6736\(20\)31094-1/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31094-1/abstract) (visited on 07/02/2020).
- [25] Russell M. Viner and Elizabeth Whittaker. “Kawasaki-like disease: emerging complication during the COVID-19 pandemic”. English. In: *The Lancet* 395.10239 (June 2020). Publisher: Elsevier, pp. 1741–1743. ISSN: 0140-6736, 1474-547X. DOI: 10.1016/S0140-6736(20)31129-6. URL: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31129-6/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31129-6/abstract) (visited on 07/02/2020).
- [26] Camila Rosat Consiglio et al. “The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19”. English. In: *Cell* 0.0 (Sept. 2020). Publisher: Elsevier. ISSN: 0092-8674, 1097-4172. DOI: 10.1016/j.cell.2020.09.016. URL: [https://www.cell.com/cell/abstract/S0092-8674\(20\)31157-0](https://www.cell.com/cell/abstract/S0092-8674(20)31157-0) (visited on 10/01/2020).
- [27] Martin Nowak and Robert M. May. *Virus Dynamics: Mathematical Principles of Immunology and Virology*. Oxford, New York: Oxford University Press, Nov. 2000. ISBN: 978-0-19-850417-7.
- [28] Dominik Wodarz. *Killer cell dynamics: mathematical and computational approaches to immunology*. English. Vol. 32. OCLC: 184908900. New York: Springer, 2007. ISBN: 9780387308937. URL: <http://site.ebrary.com/id/10183257> (visited on 06/26/2020).
- [29] Yoram Louzoun. “The evolution of mathematical immunology”. In: *Immunological Reviews* 216.1 (2007), pp. 9–20. DOI: 10.1111/j.1600-065X.2006.00495.x. eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-065X.2006.00495.x>. URL: <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-065X.2006.00495.x>.
- [30] Mario Castro, Grant Lythe, Carmen Molina-Paris, and Ruy M. Ribeiro. “Mathematics in modern immunology”. In: *Interface Focus* 6.2 (2016), p. 20150093. DOI: 10.1098/rsfs.2015.0093. eprint: <https://royalsocietypublishing.org/doi/pdf/10.1098/rsfs.2015.0093>. URL: <https://royalsocietypublishing.org/doi/abs/10.1098/rsfs.2015.0093>.
- [31] Raluca Eftimie, Joseph J. Gillard, and Doreen A. Cantrell. “Mathematical Models for Immunology: Current State of the Art and Future Research Directions”. In: *Bulletin of Mathematical Biology* 78.10 (Oct. 2016), pp. 2091–2134. ISSN: 1522-9602. DOI: 10.1007/s11538-016-0214-9. URL: <https://doi.org/10.1007/s11538-016-0214-9>.
- [32] Francois-Xavier Lescure et al. “Clinical and virological data of the first cases of COVID-19 in Europe: a case series”. English. In: *The Lancet Infectious Diseases* 20.6 (June 2020). Publisher: Elsevier, pp. 697–706. ISSN: 1473-3099, 1474-4457. DOI: 10.1016/S1473-3099(20)30200-0. URL: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30200-0/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30200-0/abstract) (visited on 07/15/2020).

- [33] Lirong Zou et al. “SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients”. In: *New England Journal of Medicine* 382.12 (Mar. 2020). Publisher: Massachusetts Medical Society .eprint: <https://doi.org/10.1056/NEJMc2001737>, pp. 1177–1179. ISSN: 0028-4793. DOI: 10.1056/NEJMc2001737. URL: <https://doi.org/10.1056/NEJMc2001737> (visited on 07/15/2020).
- [34] Quan-Xin Long et al. “Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections”. en. In: *Nature Medicine* (June 2020). Publisher: Nature Publishing Group, pp. 1–5. ISSN: 1546-170X. DOI: 10.1038/s41591-020-0965-6. URL: <https://www.nature.com/articles/s41591-020-0965-6> (visited on 07/15/2020).
- [35] Jeffrey Seow et al. *Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection*. en. preprint. Infectious Diseases (except HIV/AIDS), July 2020. DOI: 10.1101/2020.07.09.20148429. URL: <http://medrxiv.org/lookup/doi/10.1101/2020.07.09.20148429> (visited on 07/20/2020).
- [36] Andrea Padoan, Chiara Cosma, Laura Sciacovelli, Diego Faggian, and Mario Plebani. “Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics”. eng. In: *Clinical Chemistry and Laboratory Medicine* 58.7 (2020), pp. 1081–1088. ISSN: 1437-4331. DOI: 10.1515/cclm-2020-0443.
- [37] Biao Tang et al. “Modelling the impact of antibody-dependent enhancement on disease severity of Zika virus and dengue virus sequential and coinfection”. In: *Royal Society Open Science* 7.4 (2020). Publisher: Royal Society, p. 191749. DOI: 10.1098/rsos.191749. URL: <https://royalsocietypublishing.org/doi/10.1098/rsos.191749> (visited on 06/16/2020).
- [38] Ewen Callaway, Heidi Ledford, and Smriti Mallapaty. “Six months of coronavirus: the mysteries scientists are still racing to solve”. en. In: *Nature* 583.7815 (July 2020). Number: 7815 Publisher: Nature Publishing Group, pp. 178–179. DOI: 10.1038/d41586-020-01989-z. URL: <https://www.nature.com/articles/d41586-020-01989-z> (visited on 07/24/2020).
- [39] David Ellinghaus et al. “The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis”. en. In: *medRxiv* (June 2020). Publisher: Cold Spring Harbor Laboratory Press, p. 2020.05.31.20114991. DOI: 10.1101/2020.05.31.20114991. URL: <https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1> (visited on 07/24/2020).
- [40] Ha Youn Lee et al. “Simulation and prediction of the adaptive immune response to influenza A virus infection”. eng. In: *Journal of Virology* 83.14 (July 2009), pp. 7151–7165. ISSN: 1098-5514. DOI: 10.1128/JVI.00098-09.

- [41] Chentong Li, Jinhu Xu, Jiawei Liu, and Yicang Zhou. “The within-host viral kinetics of SARS-CoV-2”. en. In: *Mathematical Biosciences and Engineering* 17.4 (2020). Company: Aims Press Distributor: Aims Press Institution: Aims Press Label: Aims Press Publisher: AIMS Press, p. 2853. DOI: 10.3934/mbe.2020159. URL: <https://www.aimspress.com/article/10.3934/mbe.2020159> (visited on 06/30/2020).
- [42] Andreas Handel, Ira M. Longini, and Rustom Antia. “Towards a quantitative understanding of the within-host dynamics of influenza A infections”. In: *Journal of the Royal Society Interface* 7.42 (Jan. 2010), pp. 35–47. ISSN: 1742-5689. DOI: 10.1098/rsif.2009.0067. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839376/> (visited on 07/15/2020).

## A Mathematical details

We describe in an incremental way the mathematical properties of the main model (1)-(5).

### A.1 Model without a virus, nor immune response

In absence of any infection the equations for the target cells are (see [28, 27]):

$$dT/dt = \Lambda - \mu T. \quad (6)$$

Since the Jacobian matrix at equilibrium (a  $1 \times 1$  matrix) is the constant  $-\mu$  therefore the equilibrium is stable, in fact any initial data  $T(0)$  will converge to the equilibrium

$$T^* = \Lambda/\mu. \quad (7)$$

### A.2 Model with virus but no immune response

We employ the basic model of virus dynamics, see [27, eq (3.1) page 18] and also [28, eqns. (2.3)-(2.4) page 26] described by the equations:

$$dT/dt = \Lambda - \mu T - \beta_0 VT, \quad (8)$$

$$dI/dt = \beta_0 VT - \delta I, \quad (9)$$

$$dV/dt = \omega I - cV. \quad (10)$$

The initial conditions are:

$$T(0) = T^* = \Lambda/\mu, \quad I(0) = 0, \quad V(0) > 0, \quad (11)$$

which express the fact that the initial state for  $T$  is the stable equilibrium seen in section A.1, there are initially no infected cells and the initial viral load is strictly positive.

It is natural to assume that the decay rate of infected cells is at least as large as the decay rate of healthy cells, i.e.,

$$\delta > \mu. \quad (12)$$

In this model, an infection is only possible if the basic reproduction ratio of the virus in the absence of immune response, defined as (cf. [27, eq. (6.2) page 53])

$$R_0 = \frac{\beta_0 \omega \Lambda}{c \delta \mu} \quad (13)$$

is strictly super-unitary, that is

$$R_0 > 1. \quad (14)$$

Otherwise, that is if  $R_0 \leq 1$ , the initial viral load can only decrease. The model has two critical points (equilibrium candidates):

- critical point:  $T = T^* = \Lambda/\mu$ ,  $V = I = 0$ . The Jacobian matrix at equilibrium is  $\begin{pmatrix} -\mu & 0 & -\beta_0 T^* \\ 0 & -\delta & \beta_0 T^* \\ 0 & \omega & -c \end{pmatrix}$ . The eigenvalues of this matrix, under condition

(14), are all real but not all negative: one of them is  $\lambda_1 = -\mu$  but the product of the other two is  $\delta c - \omega \beta_0 T^* \leq 0$  thus at least one is positive. Therefore this critical point is not an equilibrium.

- critical point called "immunosuppression" state:

$$T = T^{is} = \frac{\delta c}{\beta_0 \mu}, \quad V = V^{is} := (R_0 - 1) \frac{\mu}{\beta_0}, \quad I = I^{is} := (R_0 - 1) \frac{c\mu}{\omega \beta_0}. \quad (15)$$

For values in table 1, we obtain :  $T^{is} = 4.55 \times 10^8$ ,  $V^{is} = 2.18 \times 10^8$  and  $I^{is} = 3.28 \times 10^5$ .

The Jacobian matrix is  $\begin{pmatrix} -\mu - \beta_0 V^{is} & 0 & -\beta_0 T^{is} \\ \beta_0 V^{is} & -\delta & \beta_0 T^{is} \\ 0 & \omega & -c \end{pmatrix}$ ; the characteristic

polynomial  $P(X) = (X + \delta)(X + c)(X + \mu + \beta_0 V^{is}) - \delta c(X + \mu)$  has the following properties:  $P(-\infty) < 0$ ,  $P(-\delta - c) = \delta c \beta_0 V^{is} > 0$ , thus it has a real root which is smaller than  $-\delta - c$ . The product of all roots is  $\delta c \beta_0 V^{is} > 0$  and the sum of all roots is  $-\delta - c - \mu - \beta_0 V^{is} < -\delta - c$ , thus the other two roots have negative real part. Therefore the equilibrium is stable.

It is important to note that the viral load  $V^{is}$  is the viral load that the infection will cause in a completely immunodeficient individual. We expect  $V^{is}$  to be significantly high, see in section A.3 for details.

### A.3 Model: virus and immune response but no enhancement

In this section we consider the model (1)-(4) with no ADE i.e.,  $\beta(A) = \beta_0$  that is  $\beta_1 = 0$ . This model is similar to other in the literature (see for instance [28, eq. (2.9) page 29] who consider also the cytotoxic effect of the immune response on the infected cells; however they do not consider virus destruction by antibodies. In particular there virus load is constant. Another similar model is [28, eqns. (8.1)-(8.3)]. With respect to the previous section here the immune response is present. It is triggered by a threshold set at

$$V^t = \sigma/a. \quad (16)$$

It is natural to suppose that the immune response threshold is a very small value and in any case a value smaller than the immunosuppression viral load  $V^{is}$  in (15). That is we can make the hypothesis that  $V^{is} > V^t$  i.e.

$$(R_0 - 1) \frac{\mu}{\beta_0} > \frac{\sigma}{a}. \quad (17)$$

The Jacobian matrix is:

$$J = \begin{pmatrix} -(\mu + \beta_0 V^{is}) & 0 & -\beta_0 T & 0 \\ \beta_0 V & -\delta & \beta_0 T & 0 \\ 0 & \omega & -(c + bA) & -bV \\ 0 & 0 & aA & aV - \sigma \end{pmatrix}. \quad (18)$$

With these provisions, one can find analytically the critical points (equilibria candidates):

1.  $T = T^* = \Lambda/\mu$ ,  $V = I = A = 0$ , which is the high dimensional analog of equilibrium (7). However, unlike in section A.1, this equilibrium is not stable any more (the determinant of the Jacobian matrix is negative when hypothesis (14) is satisfied).
2. the immunosuppression equilibrium (15) with  $A = 0$ ; again this equilibrium is not stable any more because the condition (17) implies that the eigenvalue  $aV^{is} - \sigma$  is positive.
3. the only critical point left is

$$T = T^{is} = \frac{\Lambda}{\mu + \beta_0 V^t}, \quad I = \frac{\beta_0 \Lambda V^t}{\delta(\mu + \beta_0 V^t)}, \quad V = V^t = \frac{\sigma}{a}, \quad A = \frac{c(V^{is} - V^t)}{\beta_0 b(\mu + \beta_0 V^t)}. \quad (19)$$

Note that the equilibrium value of the antibody level is positive due to condition (17). For values in table 1 we obtain  $T = 993976$ ,  $I = 1988$ ,  $V = 10000$ ,  $A = 39$  and the Jacobian matrix evaluated at this equilibrium is :

$$\begin{pmatrix} -3.32 \times 10^{-2} & 0 & -1.99 \times 10^{-2} & 0 \\ 2.0 \times 10^{-4} & -1.0 \times 10^{-1} & 1.99 \times 10^{-2} & 0 \\ 0 & 2.0 \times 10^3 & -3.98 \times 10^2 & -1.0 \times 10^5 \\ 0 & 0 & 2.37 \times 10^{-5} & 0 \end{pmatrix}$$

The eigenvalues are  $-3.98 \times 10^2$ ,  $-3.27 \times 10^{-2}$ ,  $-3.20 \times 10^{-3} \pm 0.024i$ . All real parts are negative thus equilibrium is stable.

#### A.4 Full model: virus, immune system and ADE

We consider the model (1)-(4) with  $\beta(A) = \beta_0 + \beta_1 A$  ( $\beta_1 > 0$ ).

The analysis of this dynamics is more involved. There are two equilibria with  $A = 0$  which are the complete analogues of the equilibria seen in previous sections and have no dynamical interest.

The critical point (19) is replaced by two critical points because the antibody level is solution of the following second order equation:

$$\omega\beta(A)\Lambda = \delta(c + bA)(\mu + \beta(A)V^t) \quad (20)$$

and

$$T = \frac{\delta(c + bA)}{\omega\beta(A)}, \quad I = \frac{V(c + bA)}{\omega}, \quad V = V^t = \frac{\sigma}{a}. \quad (21)$$

Note however that equation (20) has exactly one positive solution (the product of roots being negative), thus only a critical point is admissible, which is the positive solution of (20) (with respect to the unknown  $A$ ), while the other values are obtained as in (21).

The Jacobian matrix is:

$$J = \begin{pmatrix} -(\beta_0 + \beta_1 A)V - \mu & 0 & -(\beta_0 + \beta_1 A)T & -\beta_1 TV \\ (\beta_0 + \beta_1 A)V & -\delta & (\beta_0 + \beta_1 A)T & \beta_1 TV \\ 0 & \omega & -(c + bA) & -bV \\ 0 & 0 & aA & aV - \sigma \end{pmatrix}. \quad (22)$$

For values in table 1 and  $\beta_1 = 10^{-10}$  we obtain  $T^* = 9925061, I^* = 2472, V^* = 10000, A^* = 49$

and the Jacobian matrix evaluated at this equilibrium is :

$$\begin{pmatrix} -3.32 \times 10^{-2} & 0 & -2.47 \times 10^{-2} & -9.92 \times 10^{-1} \\ 2.49 \times 10^{-4} & -1.0 \times 10^{-1} & 2.47 \times 10^{-2} & 9.92 \times 10^{-1} \\ 0 & 2.0 \times 10^3 & -4.95 \times 10^2 & -1.0 \times 10^5 \\ 0 & 0 & 2.95 \times 10^{-5} & 0 \end{pmatrix}$$

The eigenvalues are  $-4.95 \times 10^2, -3.27 \times 10^{-2}, -3.27 \times 10^{-3} \pm 0.022i$ . All real parts are negative thus equilibrium is stable.

## A.5 Dynamical aspects

The equilibrium analysis in the previous sections does not yet tell the full story of the evolution of the system (1)-(4). Depending on the parameters, a common behavior is the following: initially  $A$  will increase as response to  $V$  being above threshold  $V^t$ ; the increase of  $A$  will drive both  $I$  and  $V$  to zero. Such a dynamics is stable over a long period and in practice  $I$  and  $V$  will keep small values for a time long enough to ensure virus clearance (when  $V$  is small enough, due to the random nature of the events,  $V$  will disappear).

Taking  $I$  and  $V$  to be constant equal to zero, the new evolution is:

$$dT/dt = \Lambda - \mu T \quad (23)$$

$$dA/dt = -\sigma A. \quad (24)$$

Note that equations for  $I$  and  $V$  are missing because if the initial states are  $V(0) = I(0) = 0$  then  $V(t) = I(t) = 0$  for all  $t \geq 0$ . This evolution drives  $T$  to  $\Lambda/\mu$  and  $A$  to zero. If however during the slow decay of  $A$  a challenge is presented

in the form of a virus load  $V > \sigma/a$  a new infection will start and  $V$  and  $I$  will rise again.

In conclusion, the stable equilibrium (20)-(21) is not necessarily reached in practice. The precise dynamics depends crucially on the parameters  $b$  and  $\beta_1$ , see main text for details.

## B Choice of simulation parameters

Parameters	Estimations	References
$\mu$	0.033	[40]
$\Lambda$	$3.3 \times 10^4$	*
$\omega$	$2.0 \times 10^3$	[32]
$\beta_0$	$2.0 \times 10^{-8}$	fit to data
$\beta_1$	0	*
$\delta$	$10^{-1}$	*
$c$	3	[41],[42]
$b$	10	fit to data
$a$	$6 \times 10^{-7}$	fit to data
$\sigma$	$6 \times 10^{-3}$	[34],[35]

Table 2: Baseline parameters and references use in numerical simulations of the model (1)-(4)

Parameters' order of magnitude were derived from literature. Parameters were then fitted to SARS-CoV-2 clinical data. The value of the parameter ' $\mu$ ' which represents the death rate of uninfected epithelial cells has been estimated for influenza host-virus dynamics which also targets lung epithelial cells, [40]. We estimated the lifespan of epithelial cells to be around one month therefore  $\mu$  to be equal to  $0.033 \text{ day}^{-1}$ . As mentioned before, the initial number of target cells is  $\frac{\Lambda}{\mu}$ . We assumed the initial number of epithelial cells to be around  $10^6$  which leads to  $3.3 \times 10^4$  cells/day for  $\Lambda$ . Parameter  $\omega$  was estimated by a graphical analysis of viral load temporal profiles in François-Xavier Lescure et al study, [32]. The mean peak viral load among five patients was taken to compute  $\omega$ . The order of magnitude of this value was graphically estimated at  $10^6$  copies/1000 cells. Therefore, the production rate of free virions was determined as  $10^3$  virions per infected cells per day. We set  $\omega$  to  $2.0 \times 10^3$  virions per infected cells per day. Clearance rate was restricted between 1 and  $10 \text{ day}^{-1}$ ,

[37],[41], and set to 3 in our simulation. The median duration of the disease for mild cases was considered to be 10 days. Hence, the lifespan of infected cells  $\delta$  was estimated to be  $10^{-1} \text{day}^{-1}$ , which is consistent with equation (12). Finally, antibody clearance rate was estimated by the results of recent studies, [34], [35] which reported that IgG started to decrease in patients within 2-3 months after infection. Therefore, we assume  $\sigma$  to be equal to  $\frac{1}{3*60} \approx 6 \times 10^{-3} \text{day}^{-1}$ .  $\beta_{0,a,b}$  and  $\beta_1$  were adjusted to best fit clinical data.

## C Sensitivity with respect to parameters

We investigate here the sensitivity of the outcomes with respect to the two main parameters, the neutralizing capacity and the ADE size and we include here for completeness, some simulations evoked in the main text.

### Sensitivity with respect to neutralizing capacity ( $b$ parameter)

We consider the nominal case and change the  $b$  parameter; the simulations results are given in figure 6 and 7.

### Sensitivity with respect to ADE ( $\beta_1$ parameter)

We consider the nominal case and change the ADE parameter  $\beta_1$ ; the simulations results are given in figure 8 and 9.




Figure 6: Initial infection for three possible values of the  $b$  parameter; the model is that in equations (1)-(4) and all other parameters have the nominal values in the table 1. We show here a zoom for the initial 50 days (see figure 7 for a longer time span).




Figure 7: Simulation in 6 for a longer time span.




Figure 8: Secondary infection with ADE mechanism present for several values of the  $\beta_1$  parameter; the model is that in equations (1)-(4) and all other parameters have the nominal values in the table 1. We show here a zoom for the initial 50 days (see figure 9 for a longer time span).




Figure 9: Simulation in 8 for a longer time span